Zobrazeno 1 - 10
of 36
pro vyhledávání: '"A V, Sass"'
Autor:
Olga A. Rakitina, Alexey I. Kuzmich, Olga A. Bezborodova, Sofia A. Kondratieva, Victor V. Pleshkan, Marina V. Zinovyeva, Dmitry A. Didych, Aleksandr V. Sass, Eugene V. Snezhkov, Maria B. Kostina, Maksim O. Koksharov, Irina V. Alekseenko
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundImmune checkpoint blockade (ICB) is rapidly becoming a standard of care in the treatment of many cancer types. However, the subset of patients who respond to this type of therapy is limited. Another way to promote antitumoral immunity is th
Externí odkaz:
https://doaj.org/article/d98d77adc9a749b981dd0cad1ef4f88c
Autor:
A. V. Sass, Irina V. Alekseenko, M. V. Zinovyeva, Dina V. Antonova, Victor V. Pleshkan, L. G. Kondratyeva
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 7
International Journal of Molecular Sciences, Vol 22, Iss 3298, p 3298 (2021)
Volume 22
Issue 7
International Journal of Molecular Sciences, Vol 22, Iss 3298, p 3298 (2021)
Cancer-associated fibroblasts (CAF) are attractive therapeutic targets in the tumor microenvironment. The possibility of using CAFs as a source of therapeutic molecules is a challenging approach in gene therapy. This requires transcriptional targetin
Autor:
Ilya V Demidyuk, Andrey V Shubin, Eugene V Gasanov, Alexander M Kurinov, Vladimir V Demkin, Tatyana V Vinogradova, Marina V Zinovyeva, Alexander V Sass, Irina B Zborovskaya, Sergey V Kostrov
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55752 (2013)
Proprotein convertases (PCs) is a protein family which includes nine highly specific subtilisin-like serine endopeptidases in mammals. The system of PCs is involved in carcinogenesis and levels of PC mRNAs alter in cancer, which suggests expression s
Externí odkaz:
https://doaj.org/article/3a114ab15b0e433188c1c32db7f726d4
Autor:
A. V. Sass, A. V. Vvedensky, Lev G. Nikolaev, Eugene D. Sverdlov, M. V. Zinovyeva, V. K. Potapov
Publikováno v:
Molecular Genetics, Microbiology and Virology. 33:187-194
Naturally occurring positively charged proteins can be promising carriers for nucleic acid transport in gene therapy. The most attractive alternative among them is histones. In this work, we describe expression and purification of recombinant human h
Autor:
O. B. Filyukova, V. V. Pleshkan, E. V. Snezhkov, Eugene D. Sverdlov, A. V. Sass, I. V. Alekseenko
Publikováno v:
Doklady Biochemistry and Biophysics. 480:158-161
An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high act
Publikováno v:
Urology & Nephrology Open Access Journal. 8:114-115
Publikováno v:
Human gene therapy methods. 28(5)
A set of vectors for Cre recombinase-dependent expression of the hybrid suicidal FCU1 transgene was constructed, including a two-plasmid system wherein the FCU1 and Cre transgenes reside in separate vectors, and single-plasmid variants in which a sin
Autor:
L. V. Dergunova, I. B. Zborovskaya, Svetlana A. Limborska, M. V. Zinovyeva, A. V. Sass, Alexandra V. Rozhkova
Publikováno v:
Molecular Biology. 48:340-346
The investigation of molecular mechanisms contributing to cancer progression is the burning problem of current research. Considerable attention has been focused on the study of gene expression in cancer cells. Sphingomyelin synthase 1 gene (SGMS1) is
Autor:
M. V. Zinovyeva, Ilya V. Demidyuk, Sergey V. Kostrov, Andrey V. Shubin, Demkin Vv, A. V. Sass, I. B. Zborovskaya, A. M. Kurinov, Tatyana V. Vinogradova
Publikováno v:
Biomarkers. 15:608-613
Objectives: Lysosomal proteases cathepsins B and D (CB and CD) play a significant part in cancer progression. For many oncological diseases protein expression levels of CB and CD have been investigated and correlations with tumour characteristics rev
Autor:
A. V. Sass, E. P. Kopantzev, R. N. Mingaleeva, Eugene D. Sverdlov, Igor P. Chernov, L. L. Zavalova
Publikováno v:
Molecular Biology. 44:448-453
Tumor-specific promoters are predominantly active and ensure expression of the gene under control exclusively in cancer cells. However, low activity of the promoters is an essential disadvantage for their therapy usage. To achieve a higher expression